Rationale for specialized nutrition support for hyperglycemic patients

Clinical Nutrition

Volumn 17, Issue SUPPL. 2, 1998, Pages 26-34

  Schrezenmeir, J ^a  

^a Kiel and Lungen Clinic Grosshansdorf   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSE; GLUCOSE; MONOUNSATURATED FATTY ACID;

COMPLICATION; DYSLIPIDEMIA; ENTERIC FEEDING; FIBER; FLUID BALANCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INDIVIDUALIZATION; LEUKOCYTE AGGREGATION; METABOLIC REGULATION; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; REVIEW; THROMBOCYTE AGGREGATION;

ENTERAL NUTRITION; FOOD, FORMULATED; HUMANS; HYPERGLYCEMIA; NUTRITIONAL SUPPORT;

EID: 0031758389     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0261-5614(98)80015-0     Document Type: Article

References (47)

1. Lasker R. The diabetes control and complications trial: implications for policy and practice (editorial). N Engl J Med 1993: 1035-1036
2. American Diabetes Association. Position statement. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1998; 21(suppl 1): S32-S35
3. Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes. Statement. Recommendations for the nutritional management of patients with diabetes mellitus. Diab Nutr Metab 1995; 8: 186-189
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
5. Eastman R C, Siebert C W, Harris M, Gorden P. Clinical review 51: implications of the Diabetes Control and Complications Trial. J Clin Endocrinol Metab 1993; 77: 1105-1107
6. Weinberger M, Kirkman S, Samsa G P et al. The relationship between glycemic control and health-related quality of life in patients with NIDDM. Med Care 1994; 32(12): 1173-1181
7. Wikblad K. Health-related quality of life in relation to metabolic control and late complications in patients with IDDM. Qual Life Res 1996; 5(1): 123-130
8. Campbell S, Schiller M. Considerations for enteral nutrition support of patients with diabetes. Top Clin Nutr 1991; 7: 23-32
9. McMahon M M, Rizza R A. Nutrition support in hospitalized patients with diabetes mellitus. Mayo Clin Proc 1996; 71(6): 587-594
10. Bak L B, Heard K A, Kearney G P. Tube feeding your diabetic patient safely. Am J Nurs 1996; 96(12): 47-49
11. McMahon M M, Bistrian B R. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995; 9(1): 1-9
12. Bagdade J, Koot R, Bulger R. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974; 23: 9-15
13. Nolan C, Beaty H. Bagdade J. Impaired granulocyte bactericidal function in patients with poorly controlled diabetes. Diabetes 1978; 127: 889-894
14. Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. N Engl J Med 1971; 284: 621-627
15. Bagdade J, Nielson K, Bulger R. Reversible abnormalities in phagocytic function in poorly controlled diabetic patients. Am J Med Sci 1972; 263: 451-456
16. Bagdade J, Stewart M, Walters E. Impaired granulocyte adherence: a reversible defect in host defense in patients with poorly controlled diabetes. Diabetes 1978; 27: 677-681
17. MacRury S M, Gemmell C G, Paterson K R, MacCuish A C. Changes in phagocytic function with glycaemic control in diabetic patients. J Clin Pathol 1989; 42: 1143-1147
18. Hosteller M K, Krueger R A, Schrneling D J. The biochemislry of opsonizalion: Central role of the reactive thioesler of the third component of complement. J Infect Dis 1984; 150: 653-661
19. 3 and Candida albicans. Diabetes 1990; 39: 271-275
20. Alexiewicz J, Kumar D, Smogorzewski M, Klin M, Massry S G. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med 1995; 123: 919-924
21. Rayfield E J, Ault M J, Keusch G T, Brothers M J, Nechemias C, Smith H. Infection and diabetes: The case for glucose control. Am J Med 1982; 72: 439-450
22. Baxter J K, Babineau T J, Apovian C M. Perioperative glucose control predicts increased nosocomial infection in diabetics. Cril Care Med 1990; 18: 5707
23. Nielson C P, Hindson D A. Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 1989; 38: 1031-1035
24. Kiley L E, Morley J, Kirk J K, Ang S D, Daly S M. Potential complications and monitoring of patients receiving total parenteral nutrition. In: Rombeau J L, Caldwell M D (Eds). Clinical Nutrition, Volume 2. Parenteral Nutrition. Philadelphia, PA: WB Saunders 1986
25. Kirk J K. The risk of hyperglycemic, hyperosmolar nonketotic coma (HHNK) in elderly patients with diabetes. Diabetes Spectrum 1993; 6: 324-325
26. Morley J E, Mooradian A D, Rosenthal M J, Kaiser F E. Diabetes mellitus in elderly patients. Is it different? Am J Med 1987; 83(3): 533-544
27. Genuth S M. The case for blood glucose control. Adv Intern Med 1995; 40: 573-623
28. Gerich J E, Campbell P J. Overview of counterregulation and its abnormalities in diabetes mellitus and other conditions. Diabetes Metab Rev 1988; 4(2): 93-111
29. Rossetti L, Giaccari A, DeFronzo R A. Glucose toxicity. Diabetes Care 1990; 13(6): 610-630
30. Sax H C, Souba W W. Enterai and parenteral feedings. Guidelines and recommendations. Med Clin North Am 1993; 77(4): 863-880
31. Carter A, Grant P. Vascular haemostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 423-432
32. Garber A J, Vinik A I, Crespin S R. Detection and management of lipid disorders in diabetic patients. Diab Care 1992; 15(8): 1068-1074
33. Barranco J. Glycemic control guidelines: current concepts. Clinical Nutrition 1998; 17(Suppl 2): 7-17
34. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stess? Metabolism 1995; 44: 363-368
35. Ceriello A, Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Diabetes 1996; 45: 471-477
36. Santini S, Marra G, Giardina B et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 1997; 46: 1853-1858
37. Jenkins A J, Klein R L, Chassereau C N, Hermayer K L, Lopes-Virella M F. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 1996; 45: 762-767
38. Jilma B, Fasching P, Ruthner C et al. Elevated circulating P-selectin in insulin-dependent diabetes mellitus. Thromb Haemost 1996; 76: 328-332
39. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries E, Yudkin J. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42
40. Lemne C, De Faire U. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996; 26(8): 692-697
41. Landin K, Stigendal L, Eriksson E et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39(10): 1044-1048
42. Mansfield M W, Heywood D M. Grant P J. Circulating levels of Factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996; 94: 2171-2176
43. Kahn N, Bauman W, Sinha A. Insulin-induced release of plasminogen activator from human blood platelets. Am J Physiol 1995; 37: H117-H124
44. Jokl R, Klein R, Lopes-Virella M, Colwell J. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care 1995; 18: 1150-1155
45. Catalano C, Muscelli E, Natali A et al. Reciprocal association between insulin sensitivity and the haematocrit in man. Eur J Clin Invest 1997; 27: 634-637
46. Trovati M, Mularoni E, Burzacca S et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995; 44: 1318-1322
47. Schneider D, Absher P, Ricci M. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation 1997; 96: 2868-2876